Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024
31 Enero 2024 - 3:05PM
Business Wire
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that
the Company will release its fourth quarter and full year 2023
financial results on Friday, March 1, 2024, prior to market open.
The Company will host a conference call and live webcast with the
investment community at 8:30 a.m. Eastern Time.
The financial results and live webcast will be accessible
through the Investor Relations section of the Company's website at
https://investors.amneal.com.
Individuals may register for the conference call by clicking the
link here. Once registered, participants will receive dial-in
details and unique PIN which will allow them to access the
call.
To access the call through a conference line, dial 1 (833)
470-1428 (in the U.S.) or for a list of toll-free international
numbers, visit this link. The access code for the call is
743629.
A replay of the conference call will be posted shortly after the
call and will be available for seven days.
About Amneal
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX), headquartered in
Bridgewater, NJ, is a fully integrated global pharmaceuticals
company. We make healthy possible through the development,
manufacturing, and distribution of a diverse portfolio of over 270
pharmaceutical products, primarily within the United States. In its
Generics segment, the Company is expanding across a broad range of
complex product categories and therapeutic areas, including
injectables and biosimilars. In its Specialty segment, Amneal has a
growing portfolio of branded pharmaceuticals focused primarily on
central nervous system and endocrine disorders, with a pipeline
focused on unmet needs. Through its AvKARE segment, the Company is
a distributor of pharmaceuticals and other products for the U.S.
federal government, retail, and institutional markets. For more
information, please visit www.amneal.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240131859245/en/
Investor Contact Anthony DiMeo Head of Investor Relations
anthony.dimeo@amneal.com
Amneal Pharmaceuticals (NYSE:AMRX)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Amneal Pharmaceuticals (NYSE:AMRX)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024